Source: Cancer Network, June 2025
Nivolumab (Opdivo) plus relatlimab demonstrated intracranial activity in patients with anti–PD-(L)1 refractory melanoma who have melanoma brain metastases, though more data is needed to confirm efficacy, according to a presentation on the phase 1/2a RELATIVITY-020 trial (NCT01968109) shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1
The clinical benefit rate was 63.0% (n = 17/27), with 3.7% of patients achieving a complete response and 18.5% achieving a partial response. The median time to intracranial response was 3.2 months (95% CI, 1.7-53.4), and the median duration of intracranial response was not reached (NR; 95% CI, 4.6-NR). Further, the overall response rate (ORR) was 22.2% (95% CI, 8.6%-42.3%); 40.7% of patients had stable disease, 18.5% had progressive disease, and 18.5% were unable to be determined.